Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 08/31
| 11-2024 | 08-2024 | 05-2024 | 02-2024 | 11-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,707 | -5,809 | -3,622 | -1,838 | -1,185 |
| Depreciation Amortization | 33 | 76 | 60 | 45 | 29 |
| Accounts receivable | -110 | -51 | -97 | -221 | -408 |
| Other Working Capital | -177 | 107 | -68 | -144 | -144 |
| Other Operating Activity | 234 | 718 | 659 | 357 | 526 |
| Operating Cash Flow | $-2,726 | $-4,959 | $-3,067 | $-1,801 | $-1,182 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -25 | -43 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -13 | -146 | -119 | -97 | -40 |
| Other Investing Activity | -13 | -146 | -119 | -97 | -40 |
| Investing Cash Flow | $-38 | $-189 | $-119 | $-97 | $-40 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,345 | 10,315 | 10,315 | 5,272 | 1,819 |
| Financing Cash Flow | $4,345 | $10,315 | $10,315 | $5,272 | $1,819 |
| Exchange Rate Effect | -3 | -20 | -22 | -21 | 4 |
| Beginning Cash Position | 6,500 | 1,352 | 1,352 | 1,352 | 1,352 |
| End Cash Position | 8,078 | 6,500 | 8,459 | 4,705 | 1,954 |
| Net Cash Flow | $1,578 | $5,148 | $7,107 | $3,353 | $602 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,726 | -4,959 | -3,067 | -1,801 | -1,182 |
| Capital Expenditure | -25 | -43 | N/A | N/A | N/A |
| Free Cash Flow | -2,751 | -5,002 | -3,067 | -1,801 | -1,182 |